162 related articles for article (PubMed ID: 28860931)
21. Antimetastatic efficacy of niosomal pentoxifylline and its combination with activated macrophages in murine B16F10 melanoma model.
Gaikwad SY; Jagtap AG; Ingle AD; Ra SG; Gude RP
Cancer Biother Radiopharm; 2000 Dec; 15(6):605-15. PubMed ID: 11190492
[TBL] [Abstract][Full Text] [Related]
22. Suramin augments the antitumor and antimetastatic activity of pentoxifylline in B16F10 melanoma.
Dua P; Ingle A; Gude RP
Int J Cancer; 2007 Oct; 121(7):1600-8. PubMed ID: 17582610
[TBL] [Abstract][Full Text] [Related]
23. Pentoxifylline inhibits T-cell adherence to keratinocytes.
Bruynzeel I; van der Raaij LM; Stoof TJ; Willemze R
J Invest Dermatol; 1995 Jun; 104(6):1004-7. PubMed ID: 7539468
[TBL] [Abstract][Full Text] [Related]
24. Determination of 3,7-dimethyl-1-(5-oxohexyl)-xanthine (pentoxifylline) and its 3,7-dimethyl-1-(5-hydroxyhexyl)-xanthine metabolite in the plasma of patients with multiple diseases using high-performance liquid chromatography.
Rieck W; Platt D
J Chromatogr; 1984 Feb; 305(2):419-27. PubMed ID: 6707169
[TBL] [Abstract][Full Text] [Related]
25. Pentoxifylline--a new drug for the treatment of intermittent claudication.
Chopra HK; Chopra KL; Aggarwal KK; Parashar SK
Indian Heart J; 1989; 41(2):127-33. PubMed ID: 2744799
[TBL] [Abstract][Full Text] [Related]
26. Pentoxifylline inhibits leukocyte infiltration and splenocyte cytotoxicity against murine colon adenocarcinoma.
Lazarczyk M; Grzela T; Niderla J; Golab J; Korczak-Kowalska G; Oldak M; Skopinski P
Oncol Rep; 2003; 10(4):839-43. PubMed ID: 12792732
[TBL] [Abstract][Full Text] [Related]
27. Effects of pentoxifylline on peritoneal fibroblasts and silica-induced peritoneal fibrosis.
Fang CC; Lai MN; Chien CT; Hung KY; Tsai CC; Tsai TJ; Hsieh BS
Perit Dial Int; 2003; 23(3):228-36. PubMed ID: 12938822
[TBL] [Abstract][Full Text] [Related]
28. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts.
Nidhyanandan S; Thippeswamy BS; Chandrasekhar KB; Reddy ND; Kulkarni NM; Karthikeyan K; Khan FR; Raghul J; Vijaykanth G; Narayanan S
Anticancer Drugs; 2017 Oct; 28(9):1002-1017. PubMed ID: 28727579
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of pro-inflammatory cytokine gene expression and papilloma growth during murine multistage carcinogenesis by pentoxifylline.
Robertson FM; Ross MS; Tober KL; Long BW; Oberyszyn TM
Carcinogenesis; 1996 Aug; 17(8):1719-28. PubMed ID: 8761432
[TBL] [Abstract][Full Text] [Related]
30. Pentoxifylline inhibits agonist-induced vasoconstriction in vascular smooth muscle and spontaneous peristalsis in isolated ileum.
Ruddock MW; Hirst DG
Oncol Res; 2005; 15(2):81-6. PubMed ID: 16119005
[TBL] [Abstract][Full Text] [Related]
31. Effect of nicotinamide and pentoxifylline on normal tissue and FSA tumor oxygenation.
Price MJ; Li LT; Tward JD; Bublik I; McBride WH; Lavey RS
Acta Oncol; 1995; 34(3):391-5. PubMed ID: 7779428
[TBL] [Abstract][Full Text] [Related]
32. Pentoxifylline attenuates the local and systemic inflammatory response after infrarenal abdominal aortic ischemia-reperfusion.
Nagy T; Hardi P; Takács I; Tóth M; Petrovics L; Jancsó G; Sínay L; Fazekas G; Pintér Ö; Arató E
Clin Hemorheol Microcirc; 2017; 65(3):229-240. PubMed ID: 27983542
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways.
Kreth S; Ledderose C; Luchting B; Weis F; Thiel M
Shock; 2010 Jul; 34(1):10-6. PubMed ID: 19997047
[TBL] [Abstract][Full Text] [Related]
34. Studies on platelet aggregation inhibitors in vivo. VIII. Effect of pentoxifylline on spontaneous tumor metastasis.
Gordon S; Witul M; Cohen H; Sciandra J; Williams P; Gastpar H; Murphy GP; Ambrus JL
J Med; 1979; 10(6):435-43. PubMed ID: 233697
[TBL] [Abstract][Full Text] [Related]
35. Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication.
Aviado DM; Dettelbach HR
Angiology; 1984 Jul; 35(7):407-17. PubMed ID: 6380349
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of anti-CD3 antibody-induced mouse T cell activation by pentoxifylline in combination with rapamycin or A77 1726 (leflunomide).
Richard M; Hoskin DW
Int J Immunopharmacol; 1998; 20(4-5):241-52. PubMed ID: 9730259
[TBL] [Abstract][Full Text] [Related]
37. The phosphodiesterase inhibitor, pentoxifylline, alters rat intestinal epithelial cell proliferation via changes in the expression of transforming growth factors.
Diab-Assef M; Reimund JM; Ezenfis J; Duclos B; Kedinger M; Foltzer-Jourdainne C
Scand J Gastroenterol; 2002 Feb; 37(2):206-14. PubMed ID: 11843059
[TBL] [Abstract][Full Text] [Related]
38. Pentoxifylline inhibits TLR- and inflammasome-mediated in vitro inflammatory cytokine production in human blood with greater efficacy and potency in newborns.
Speer EM; Dowling DJ; Ozog LS; Xu J; Yang J; Kennady G; Levy O
Pediatr Res; 2017 May; 81(5):806-816. PubMed ID: 28072760
[TBL] [Abstract][Full Text] [Related]
39. Suppression of angiogenic activity of sera from diabetic patients with non-proliferative retinopathy by compounds of herbal origin and sulindac sulfone.
Skopinski P; Szaflik J; Duda-Król B; Nartowska J; Sommer E; Chorostowska-Wynimko J; Demkow U; Skopinska-Rózewska E
Int J Mol Med; 2004 Oct; 14(4):707-11. PubMed ID: 15375605
[TBL] [Abstract][Full Text] [Related]
40. Prevention studies with pentoxifylline: new clinical projects.
Eugène-Jolchine I; Milpied N
J Cardiovasc Pharmacol; 1995; 25 Suppl 2():S143-6. PubMed ID: 8699855
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
